Exelixis Inc (EXEL) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Total Cash From Operating Activities Chart for Exelixis Inc
Exelixis Inc (EXEL) operating cash flow for FY2025 was USD 884.3M, a 26.3% change from FY2024. Exelixis Inc's operating cash flow moved from USD -7.3M in 1999 to USD 884.3M in 2025 over 26 years. Operating cash flow compound annual growth rate: 5-year CAGR of 33.4%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $14.45B
- Implied Share Price
- $58.33
- Enterprise Value
- $13.38B
- Revenue (TTM)
- $2.44B
- EBITDA
- $1.02B
- Profit Margin
- 35.33%
- Trailing P/E
- 18.58
- Forward P/E
- 13.55
- Price/Book (MRQ)
- 7.82
- Price/Sales (TTM)
- 5.93
- EV/EBITDA
- 13.11
- EV/Revenue
- 5.49
- Dividend Yield
- —
- Book Value
- $7.41
- Free Cash Flow (FY2025)
- $844.34M
- Free Cash Flow Yield
- 5.84%
Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.